Risk factors for functional decline among survivors of Gram-negative bloodstream infection: A prospective cohort study

PLoS One. 2021 Nov 17;16(11):e0259707. doi: 10.1371/journal.pone.0259707. eCollection 2021.

Abstract

Objective: To identify risk factors for functional decline after hospitalization for Gram-negative bacteremia.

Patients and methods: A prospective cohort study based on a randomized controlled trial conducted between January 1, 2013 and August 31, 2017 in Israel and Italy. Hospitalized patients with Gram-negative bacteremia who survived until day 90 and were not bedridden at baseline were included. The primary end point was functional decline at 90 days.

Results: Five hundred and nine patients were included. The median age of the cohort was 71 years (interquartile range [IQR], 60-80 years), 46.4% (236/509) were male and 352 of 509 (69%) patients were independent at baseline. Functional decline at 90 days occurred in 24.4% of patients (124/509). In multivariable analysis; older age (odds ratio [OR], 1.03; for an one-year increment, 95% confidence interval [CI] 1.01-1.05), functional dependence in instrumental activities of daily living at baseline (OR, 4.64; 95% CI 2.5-8.6), low Norton score (OR, 0.87; 95% CI 0.79-0.96) and underlying comorbidities: cancer (OR, 2.01; 95% CI 1.14-3.55) and chronic pulmonary disease (OR, 2.23 95% CI 1.12-4.42) and longer length of hospital stay (OR 1.09; for one-day increment, 95% CI 1.04-1.15) were associated with functional decline. Appropriate empirical antibiotic treatment was associated with lower rates of functional decline within 90 days (OR, 0.4; 95% CI 0.21-0.78).

Conclusions: Patients surviving bloodstream infections have poor long term trajectories after clinical recovery and hospital discharge. This has vast implications for patients, their family members and health policy makers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use
  • Confidence Intervals
  • Female
  • Gram-Negative Bacteria / drug effects
  • Gram-Negative Bacteria / pathogenicity*
  • Humans
  • Lung Diseases / blood*
  • Lung Diseases / drug therapy
  • Lung Diseases / microbiology*
  • Male
  • Middle Aged
  • Prospective Studies
  • Risk Factors

Substances

  • Anti-Bacterial Agents

Grants and funding

This work was supported in part by The Israeli Ministry of Science, Technology and Space research, grant agreement number 3-12075 awarded to NER and MP. https://www.gov.il/en/departments/ministry_of_science_and_technology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.